CYTK CYTOKINETICS INC Insider Trading

EVP Andrew Callos sells 15,000 shares ($1.1M) at $74.08 via scheduled 10b5-1 plan; retains 58,555 shares plus 39,000 option rights.

Andrew Callos, EVP and Chief Commercial Officer, sold 15,000 shares for $1,111,200.00 on 2026-06-01 at $74.08 per share as part of a pre-arranged 10b5-1 trading plan, reducing his non-derivative holdings to 58,555 shares while retaining 39,000 non-qualified stock option rights. Stock price at transaction was $74.08; current price is $73.68, with the stock trading -8.1% from its 52-week high of $80.20 but +16.3% over the prior 30 days and +21.3% over the prior 90 days. Callos's prior five sales at CYTK show mixed timing outcomes: three consecutive sells in early 2026 were followed by +18.1%, +7.9%, and +7.8% respective 30-day returns, while a December 2025 sale preceded a -6.4% 30-day decline and a March 2025 sale preceded a -11.4% 30-day decline. The company posted $19,355,000.00 in latest-quarter revenue but remains unprofitable with $-206,031,000.00 net income for the most recent full fiscal year, though annual revenue growth reached +376.6% year-over-year. As a scheduled trade under a 10b5-1 plan, this sale reflects administrative scheduling rather than discretionary market timing decisions.

CEO Robert I Blum sold 7,500 shares (7.5K shares) of CYTK at $77.21 (scheduled 10b5-1 plan)

Robert I Blum, President & CEO of Cytokinetics Inc, sold 7,500 shares (7.5K shares) worth $579,075.00 ($579.1K) on 2026-05-27 as part of a pre-arranged 10b5-1 trading plan, reducing holdings from 400,330 shares (400.3K shares) to 392,830 shares (392.8K shares). The sale occurred near the 52-week high of $80.20 (stock is -4.2% from peak), following a strong 30-day gain of +26.6% and 90-day gain of +23.4%. Because this transaction is scheduled under a 10b5-1 plan rather than discretionary, it reflects pre-determined execution rather than a current market judgment. The company is unprofitable (net income $-206.0M in latest full year) despite significant revenue growth of +376.6% year-over-year, leaving operational cash generation as a key consideration for investors monitoring executive position changes.

CEO Robert I Blum sold 7,500 shares at $77.92 via 10b5-1 plan; stock near 52-week high ($80.20)

Robert I Blum, President & CEO of Cytokinetics Inc, sold 7,500 shares for $584,400 through a pre-arranged 10b5-1 trading plan on 2026-05-14, reducing holdings to 400,330 shares. This is a scheduled, non-discretionary transaction executed near the stock's 52-week high of $80.20 (current price $78.64 is -2.0% from peak), suggesting the sale was mechanically triggered by plan parameters rather than a discretionary timing decision by the insider. While Blum's historical sell track record shows a 50.00% well-timed rate with negative average returns at 30 days (-0.2%) and 90 days (-3.4%), the 10b5-1 framework precludes inferring conviction or strategic intent from this particular transaction. Investors should note the company remains deeply unprofitable with -$206.0M net income despite exceptional 376.6% annual revenue growth, making the valuation and execution timing context less material than the mechanical nature of the trade plan.

CFO Lee Sung sells ~$1.84M in CYTK stock—substantial position reduction amid unprofitable operations and weak recent price momentum.

Lee Sung, Cytokinetics' Chief Financial Officer, sold approximately 27% of his holdings in a single transaction, generating $1.84 million in proceeds. The timing is notable: the stock is currently trading slightly below its recent highs but still well above its annual lows, and over the past month it has shown minimal downward pressure. However, the company's underlying fundamentals present a concerning picture—the business is unprofitable with a substantial annual net loss, and recent revenue figures suggest significant year-over-year contraction. When a C-suite executive of an unprofitable company exits a meaningful portion of their stake, it warrants attention, especially when the stock's price strength might otherwise mask financial deterioration. The sale appears deliberate and material enough to signal caution, though it does not constitute an emergency signal; this is a CFO managing personal wealth at a company burning cash, not a catastrophic red flag.

Director John Henderson exercised options and sold entire tranche same-day, net neutral on shares.

Director John Henderson executed an option exercise and immediate sale on the same day, acquiring shares at a substantial discount to the sale price but maintaining a flat net position in the company. The company is unprofitable with significant recent revenue headwinds, and the stock has recovered roughly 15% over the recent quarter while still trading modestly below its 52-week high. Henderson's selling activity is consistent with his prior pattern—this is his eighth open-market sale in the past three years—and the mechanics of this trade (exercise-and-sell) appear designed to harvest the spread between option strike and current market value rather than to adjust his equity stake. The timing during a period of price strength may suggest willingness to exit at elevated valuations, but without disclosure of his exercise motivations or cost basis on the original grant, the trade primarily reflects routine option vesting and liquidity management rather than a significant shift in his confidence in the company.

Chief Commercial Officer exercises and immediately sells 15,857 shares at profit; pure stock-compensation monetization with no net position change.

Andrew Callos, EVP and Chief Commercial Officer, exercised and sold 15,857 shares on the same day, resulting in zero net change to his stockholding. This is a routine stock-compensation exercise: he converted equity awards into shares and immediately liquidated them at a gain. His 29 open-market sales over three years against zero open-market purchases reveal a consistent pattern of exercising vested compensation and selling—not a pattern of convictions about the stock's direction. His prior four sales at this company show mixed timing, with two followed by stock declines and two followed by gains. The company's fundamentals show losses and significant recent revenue decline, making this exercise-and-sell a straightforward liquidity event rather than a statement about company prospects. Given the repetitive nature of his trades and the lack of any accumulated position, this filing is routine insider compensation realization.